Mubadala Acquires €200 Million Shares in German Pharmaceutical

Evotec has continuously expanded its operations internationally. WAM
Evotec has continuously expanded its operations internationally. WAM
TT

Mubadala Acquires €200 Million Shares in German Pharmaceutical

Evotec has continuously expanded its operations internationally. WAM
Evotec has continuously expanded its operations internationally. WAM

Mubadala Investment Company has announced that it is pumping 200 million euros into Evotec SE, a German pharmaceutical company that specializes in drug discovery solutions.

Evotec SE said that it resolved a capital increase from its authorized capital without pre-emptive rights against cash. Evotec will issue a total of 11,478,298 new shares to Mubadala Investment Company and Novo Holdings A/S, increasing Evotec’s cash reserves by €250 million in total.

In this private placement capital increase, Mubadala Investment Company, a sovereign investor with an entrepreneurial mind-set and a long-standing history of strategic investments in the healthcare sector, will invest €200 million to subscribe for approx. 5.6 % of outstanding Evotec shares.

Evotec’s existing shareholder Novo Holdings A/S also will invest €50 million to support Evotec’s accelerated growth ambition and to reinforce its ownership in the company of approx. 11.0% of outstanding shares.

Evotec has developed a unique strategy to become the global leading platform company for the modality-agnostic development of innovative first-in-class and best-in-class therapeutic approaches resulting in a large co-owned pipeline.

Evotec has continuously expanded its operations internationally with more than 3,400 employees at 14 global sites in Germany, USA, France, Italy, UK, and Austria.

By leveraging its proprietary platforms within a comprehensive network of high-value partnerships, Evotec aims to improve global access to more precise and effective medicines. Future investments will accelerate Evotec’s underlying business strategy and enable the company’s next strategic growth phase.

"We welcome Mubadala to our group of strategic investors. There is no reason for us to slow down our mission in spite of the ongoing pandemic. We can and want to grow even faster and see a lot of positive momentum in our business strategy,” said Dr. Werner Lanthaler, Chief Executive Officer of Evotec.

“We are delighted that Mubadala has chosen to invest in Evotec with a long-term view. Also, we are pleased to see that Novo Holdings A/S continues to support our strategy. This investment allows us to further accelerate our strategy to create the world-leading "R&D Autobahn to Cures" from discovery to commercial manufacturing,” Emirates News Agency (WAM) quoted him as saying.

Chief Financial Officer of Evotec Enno Spillner said that with this commitment by existing and new investors, “our liquidity reserves will total more than €500 m.”

“This placement will generate a net cash position of more than €150 m (excluding IFRS 16) with Evotec’s net-debt leverage turning negative (excluding IFRS 16). Our equity ratio will strengthen to above 50%. While maintaining our business outlook for 2020, the very positive impact of this transaction on our balance sheet structure will increase our flexibility and makes us even better prepared for our accelerated global expansion steps."



China’s Economy Meets Official Growth Target, but Many Feel a Downturn

 People shop around at a market in Beijing, Thursday, Jan. 16, 2025. (AP)
People shop around at a market in Beijing, Thursday, Jan. 16, 2025. (AP)
TT

China’s Economy Meets Official Growth Target, but Many Feel a Downturn

 People shop around at a market in Beijing, Thursday, Jan. 16, 2025. (AP)
People shop around at a market in Beijing, Thursday, Jan. 16, 2025. (AP)

China's economy matched the government's ambitions for 5% growth last year, but in a lopsided fashion, with many people complaining of worsening living standards as Beijing struggles to transfer its industrial and export gains to consumers.

The unbalanced growth raises concerns that structural problems may deepen further in 2025, when China plans a similar growth performance by going deeper into debt to counter the impact of an expected US tariff hike, potentially as soon as Monday when Donald Trump is inaugurated as president.

China's December data showed industrial output far outpacing retail sales, and the unemployment rate ticking higher, highlighting the supply-side strength of an economy running a trillion-dollar trade surplus, but also its domestic weakness.

The export-led growth is partly underpinned by factory gate deflation which makes Chinese goods competitive on global markets, but also exposes Beijing to greater conflicts as trade gaps with rival countries widen. Within borders, falling prices have ripped into corporate profits and workers incomes.

Andrew Wang, an executive in a company providing industrial automation services for the booming electrical vehicle sector, said his revenues fell 16% last year, prompting him to cut jobs, which he expects to do again soon.

"The data China released was different from what most people felt," Wang said, comparing this year's outlook with notching up the difficulty level on a treadmill.

"We need to run faster just to stay where we are."

China's National Bureau of Statistics and the State Council Information Office, which handles media queries for the government, did not immediately respond to questions about the doubts over official data.

If the bulk of the extra stimulus Beijing has lined up for this year keeps flowing towards industrial upgrades and infrastructure, rather than households, it could exacerbate overcapacity in factories, weaken consumption, and increase deflationary pressures, analysts say.

"It seems dubious that China precisely hit its growth target for 2024 at a time when the economy continues to face tepid domestic demand, persistent deflationary pressures, and flailing property and equity markets," said Eswar Prasad, trade policy professor at Cornell University and a former China director at the International Monetary Fund.

"Looking ahead, China not only faces significant domestic challenges but also a hostile external environment."

'UNEASE'

Chinese exporters expect higher tariffs to have a much greater impact than during Trump's first term, accelerating a reshoring of production abroad and further shrinking profits, hurting jobs and private sector investment.

A trade war 2.0 would find China in a much more vulnerable position than when Trump first raised tariffs in 2018, as it still grapples with a deep property crisis and huge local government debt, among other imbalances.

So far, Beijing has pledged to prioritize domestic consumption in this year's policies, but has revealed little apart from a recently-expanded trade-in program that subsidizes purchases of cars, appliances and other goods.

China gave civil servants their first big pay bump in a decade, although the higher estimates measure the overall increase at roughly 0.1% of GDP. Financial regulators got steep wage cuts, as have many others in the private sector.

For Jiaqi Zhang, a 25-year-old investment banker in Beijing, 2024 felt like a downturn, having seen her salary trimmed for a second consecutive year, bringing the total reduction to 30%. Eight or nine of her colleagues lost their jobs, she said.

"There is a general feeling of unease in the company," said Zhang, who has cut back on buying clothes and dining out. "I'm ready to leave at any time, just that there's nowhere to go right now."

SCEPTICISM

The world's second-largest economy beat economists' 2024 forecast of 4.9% growth. Its fourth-quarter 5.4% pace was the quickest since early 2023.

"China's economy is showing signs of revival, led by industrial output and exports," said Frederic Neumann, chief Asia economist at HSBC.

But the last-minute bounce in growth may already have been flattered by front-loading of shipments to the US ahead of any new tariffs, which will inevitably lead to a pay-back, he said.

"There will be an even bigger need to apply domestic stimulus" this year, Neumann said.

China and Hong Kong shares rose slightly, but the yuan lingered near 16-month lows, under pressure from sliding Chinese bond yields and the tariff threat.

Subdued markets reflect wavering confidence in China's outlook, analysts said.

Beijing has rarely missed its growth targets. The last time was in 2022 due to the pandemic.

"Are investors around the world going to invest in China because they hit 5%? No," said Alicia Garcia-Herrero, chief economist for Asia Pacific at Natixis, who expects slower 2025 growth. "So it's becoming an irrelevant target."

Also, long-standing skepticism about the accuracy of official data has shifted into higher gear over the past month.

A bearish commentary by Gao Shanwen, a prominent Chinese economist who spoke of "dispirited youth" and estimated that GDP growth may have been overstated by 10 percentage points between 2021 and 2023, vanished from social media after going viral.

In a Dec. 31 note, Rhodium Group estimated that China's economy only grew 2.4%-2.8% in 2024, pointing to the disconnect between relatively stable official figures throughout the year and the flood of stimulus unleashed from about the mid-way mark.

This included May's blockbuster property market package, the most aggressive monetary policy easing steps since the pandemic in September and a 10 trillion yuan ($1.36 trillion) debt package for local governments in November.

"If China's actual growth is below headline rates, it suggests there is a broader problem of China's domestic demand that is contributing to global trade tensions," Rhodium partner Local Wright told Reuters.

"Overcapacity would be a far less pressing issue if China's economy was actually growing at 5% rates."